Newton, Massachusetts – October 2016.
NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds announces the presentation of a case study entitled “A Comparison of Different Development Paths, Challenges and the Profiles of Three Repositioned Drugs” at the Strategic Partnerships in Drug Repurposing conference in Boston taking place at the Wyndham Boston Beacon Hill during October 27-28, 2016. The CEO of NeuroHealing Pharmaceuticals, Neal M. Farber, Ph.D. will give a talk examining the use of divergent drug mechanisms, delivery means and the needs of patients in relation to three repositioned product candidates. He will illustrate the contrasting risk attenuation features, IP strategies, market size, sales force and regulatory issues involved of three drugs under development.